Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS. Grandal B, et al. Among authors: de croze d. Cancers (Basel). 2020 Dec 8;12(12):3681. doi: 10.3390/cancers12123681. Cancers (Basel). 2020. PMID: 33302444 Free PMC article.
No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis.
Simon V, Laot L, Laas E, Rozette S, Guerin J, Balezeau T, Nicolas M, Pierga JY, Coussy F, Laé M, De Croze D, Grandal B, Abecassis J, Dumas E, Lerebours F, Reyal F, Hamy AS. Simon V, et al. Among authors: de croze d. Cancers (Basel). 2020 Oct 12;12(10):2943. doi: 10.3390/cancers12102943. Cancers (Basel). 2020. PMID: 33053866 Free PMC article.
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS, Bonsang-Kitzis H, De Croze D, Laas E, Darrigues L, Topciu L, Menet E, Vincent-Salomon A, Lerebours F, Pierga JY, Brain E, Feron JG, Benchimol G, Lam GT, Laé M, Reyal F. Hamy AS, et al. Among authors: de croze d. Clin Cancer Res. 2019 Nov 15;25(22):6731-6741. doi: 10.1158/1078-0432.CCR-18-3017. Epub 2019 Sep 12. Clin Cancer Res. 2019. PMID: 31515462
Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer.
Hamy AS, Derosa L, Valdelièvre C, Yonekura S, Opolon P, Priour M, Guerin J, Pierga JY, Asselain B, De Croze D, Pinheiro A, Lae M, Talagrand LS, Laas E, Darrigues L, Grandal B, Marangoni E, Montaudon E, Kroemer G, Zitvogel L, Reyal F. Hamy AS, et al. Among authors: de croze d. Oncoimmunology. 2019 Nov 14;9(1):1677427. doi: 10.1080/2162402X.2019.1677427. eCollection 2020. Oncoimmunology. 2019. PMID: 32002287 Free PMC article.
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F. Hamy AS, et al. Among authors: de croze d. PLoS One. 2020 Jun 24;15(6):e0234191. doi: 10.1371/journal.pone.0234191. eCollection 2020. PLoS One. 2020. PMID: 32579551 Free PMC article.
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Floris G, Richard F, Hamy AS, Jongen L, Wildiers H, Ardui J, Punie K, Smeets A, Berteloot P, Vergote I, De Croze D, Meseure D, Salomon A, Laé M, Reyal F, Biganzoli E, Neven P, Desmedt C. Floris G, et al. Among authors: de croze d. J Natl Cancer Inst. 2021 Feb 1;113(2):146-153. doi: 10.1093/jnci/djaa090. J Natl Cancer Inst. 2021. PMID: 33152071 Free PMC article.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S; I-SPY 2 Trial Consortium; Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Yau C, et al. Among authors: de croze d. Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11. Lancet Oncol. 2022. PMID: 34902335 Free PMC article.
[Molecular characterization of breast cancer in clinical practice].
Zemmouri Y, De Croze D, Vincent Salomon A, Rouzier R, Bonneau C. Zemmouri Y, et al. Among authors: de croze d. Gynecol Obstet Fertil. 2016 May;44(5):285-92. doi: 10.1016/j.gyobfe.2016.03.010. Epub 2016 Apr 14. Gynecol Obstet Fertil. 2016. PMID: 27150068 Review. French.
[Atypical fibroxanthoma].
Péron J, Depaepe L, Decroze D, Jaouen A, Dalle S, Balme B. Péron J, et al. Ann Dermatol Venereol. 2014 Dec;141(12):786-9. doi: 10.1016/j.annder.2014.05.006. Epub 2014 Aug 4. Ann Dermatol Venereol. 2014. PMID: 25433934 Review. French. No abstract available.
11 results